



## Liste des publication récentes du Dr Marc Espié

1: Groheux D, Giacchetti S, Espié M, Rubello D, Moretti JL, Hindié E. Early monitoring of response to neoadjuvant chemotherapy in breast cancer with 18F-FDG PET/CT: defining a clinical aim. *Eur J Nucl Med Mol Imaging*. 2011 Mar;38(3):419-25.

2: Groheux D, Giacchetti S, Moretti JL, Porcher R, Espié M, Lehmann-Che J, de Roquancourt A, Hamy AS, Cuvier C, Vercellino L, Hindié E. Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. *Eur J Nucl Med Mol Imaging*. 2011 Mar;38(3):426-35. Epub 2010 Nov 6.

3: Biganzoli L, Di Vincenzo E, Jiang Z, Lichinitser M, Shen Z, Delva R, Bogdanova N, Vivanco GL, Chen Z, Cheng Y, Just M, Espié M, Vinholes J, Hamm C, Crivellari D, Chmielowska E, Semiglazov V, Dalenc F, Smith I. First-line bevacizumab-containing therapy for breast cancer: results in patients aged  $\geq 70$  years treated in the ATHENA study. *Ann Oncol*. 2012 Jan;23(1):111-8. Epub 2011 Mar 28.

4: de Bazelaire C, Pluvinage A, Chapelier M, Hamy AS, Albiter M, Farges C, Bourrier P, Zagdanski AM, Espié M, de Kerviler E, Frija J. [Diffusion-weighted MR imaging of the breast]. *J Radiol*. 2010 Mar;91(3 Pt 2):394-404; quiz 405-7. Review. French.

5: Pierga JY, Delaloge S, Espié M, Brain E, Sigal-Zafrani B, Mathieu MC, Bertheau P, Guinebretière JM, Spielmann M, Savignoni A, Marty M. A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. *Breast Cancer Res Treat*. 2010 Jul;122(2):429-37. Epub 2010 May 18.

6: Lehmann-Che J, André F, Desmedt C, Mazouni C, Giacchetti S, Turpin E, Espié M, Plassa LF, Marty M, Bertheau P, Sotiriou C, Piccart M, Symmans WF, Pusztai L, de Thé H. Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers. *Oncologist*. 2010;15(3):246-52. Epub 2010 Mar 12.

7: Calderaro J, Espie M, Duclos J, Giacchetti S, Wehrer D, Sandid W, Cahen-Doidy L, Albiter M, Janin A, de Roquancourt A. Breast intracystic papillary carcinoma: an update. *Breast J*. 2009 Nov-Dec;15(6):639-44. Epub 2009 Sep 7. Erratum in: *Breast J*. 2009 Nov-Dec;15(6):687.

8: Tubiana-Mathieu N, Bougnoux P, Becquart D, Chan A, Conte PF, Majois F, Espie M, Morand M, Vaissiere N, Villanova G. All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial. *Br J Cancer*. 2009 Jul 21;101(2):232-7. Epub 2009 Jul 7.



9: Bertheau P, Espié M, Turpin E, Lehmann J, Plassa LF, Varna M, Janin A, de Thé H. TP53 status and response to chemotherapy in breast cancer. *Pathobiology*. 2008;75(2):132-9. Epub 2008 Jun 10. Review.

10: Groheux D, Moretti JL, Baillet G, Espie M, Giacchetti S, Hindie E, Hennequin C, Vilcoq JR, Cuvier C, Toubert ME, Filmont JE, Sarandi F, Misset JL. Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer. *Int J Radiat Oncol Biol Phys*. 2008 Jul 1;71(3):695-704. Epub 2008 Apr 23.

11: Lerebours F, Vacher S, Andrieu C, Espie M, Marty M, Lidereau R, Bieche I. NF-kappa B genes have a major role in inflammatory breast cancer. *BMC Cancer*. 2008 Feb 4;8:41.

12: Varna M, Soliman H, Feugeas JP, Turpin E, Chapelin D, Legrès L, Plassa LF, de Roquancourt A, Espié M, Misset JL, Janin A, de Thé H, Bertheau P. Changes in allelic imbalances in locally advanced breast cancers after chemotherapy. *Br J Cancer*. 2007 Oct 22;97(8):1157-64. Epub 2007 Sep 18.

13: Espié M, Daures JP, Chevallier T, Mares P, Micheletti MC, De Reilhac P. Breast cancer incidence and hormone replacement therapy: results from the MISSION study, prospective phase. *Gynecol Endocrinol*. 2007 Jul;23(7):391-7.

14: Bertheau P, Turpin E, Rickman DS, Espié M, de Reyniès A, Feugeas JP, Plassa LF, Soliman H, Varna M, de Roquancourt A, Lehmann-Che J, Beuzard Y, Marty M, Misset JL, Janin A, de Thé H. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. *PLoS Med*. 2007 Mar;4(3):e90.